Document is current
Any future updates will be listed below
-
Authors
Klebanoff, Christopher A. https://orcid.org/0000-0001-9645-3896
Chandran, Smita S.
Baker, Brian M. https://orcid.org/0000-0002-0864-0964
Quezada, Sergio A.
Ribas, Antoni https://orcid.org/0000-0003-3669-8458
- License Information
-
More Information
Article History
Accepted: 8 September 2023
First Online: 27 October 2023
Competing interests
: C.A.K. and S.S.C. are inventors on patents related to T cell receptor (TCR) discovery and public neoantigen-specific TCRs and are recipients of licensing revenue from Intima Bioscience shared according to Memorial Sloan Kettering Cancer Center (MSKCC) institutional policies. C.A.K. has consulted for or is on the scientific advisory boards for Achilles Therapeutics, Affini-T Therapeutics, Aleta BioTherapeutics, Bellicum Pharmaceuticals, Bristol Myers Squibb, Catamaran Bio, Cell Design Labs, Decheng Capital, G1 Therapeutics, Klus Pharma, Obsidian Therapeutics, PACT Pharma, Roche/Genentech and T-knife, and is a scientific co-founder and equity holder in Affini-T Therapeutics. S.S.C. is a scientific advisor and equity holder in Affini-T Therapeutics. B.M.B. is an inventor on patents related to TCR engineering and neoantigen discovery, has consulted for Eureka Therapeutics and EnaraBio, and is on the scientific advisory board of T-cure Bioscience. S.A.Q is an inventor in patents related to the use of T cell therapies targeting tumour clonal neoantigens in cancer, and is also a founder, CSO and equity holder of Achilles Therapeutics. A.R. reports personal fees from Amgen, Chugai, Genentech, Merck, Novartis, Roche, Sanofi, Vedanta, 4C Biomed, Appia, Apricity, Arcus, Highlight, Compugen, ImaginAb, Kalthera/ImmPACT Bio, MapKure, Merus, Rgenix, Lutris, Nextech, PACT Pharma, Synthekine, Tango, Advaxis, CytomX, Five Prime, RAPT, Isoplexis and Kite/Gilead, and has received grants from Agilent and Bristol Myers Squibb outside the submitted work.
